By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Starbucks' new 'Bearista' cup is causing a stir — and is being listed on eBay for $600 - 2Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- 3Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- 4Bombardier Global 8000 Enters Service
- 5Opening Potential: Self-awareness and Long lasting Learning
- She was the supermodel dubbed 'The Face' in the '80s. Joining OnlyFans in her 60s taught her a lot.
- Public Parks in the USA
- Alleged Huione Group Money Laundering Boss Extradited to China
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- Poland open to German troops to help secure Ukraine ceasefire
- Finding Your Motivation: Moves toward a Satisfying Life
- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- I watched more than 500 new movies this year. These are the 25 best ones.
- AI is making spacecraft propulsion more efficient – and could even lead to nuclear-powered rockets
